165 related articles for article (PubMed ID: 34224163)
1. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States.
Wijarnpreecha K; Li F; Xiang Y; Xu X; Zhu C; Maroufy V; Wang Q; Tao W; Dang Y; Pham HA; Zhou Y; Li J; Zhang X; Xu H; Taner CB; Yang L; Tao C
Aliment Pharmacol Ther; 2021 Aug; 54(4):481-492. PubMed ID: 34224163
[TBL] [Abstract][Full Text] [Related]
2. Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation.
Cheng HY; Lin HC; Lin HL; Uang YS; Keller JJ; Wang LH
Front Pharmacol; 2021; 12():805318. PubMed ID: 35069216
[No Abstract] [Full Text] [Related]
3. The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis.
Herrera I; Pascual S; Zapater P; Carnicer F; Bellot P; María Palazón J
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1194-7. PubMed ID: 27294486
[TBL] [Abstract][Full Text] [Related]
4. Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Kim TW; Kim HJ; Chon CU; Won HS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
Clin Mol Hepatol; 2012 Jun; 18(2):203-12. PubMed ID: 22893871
[TBL] [Abstract][Full Text] [Related]
5. Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.
He X; Zhao Z; Jiang X; Sun Y
Front Pharmacol; 2023; 14():1216059. PubMed ID: 37538177
[No Abstract] [Full Text] [Related]
6. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.
Onali S; Kalafateli M; Majumdar A; Westbrook R; O'Beirne J; Leandro G; Patch D; Tsochatzis EA
Liver Int; 2017 Sep; 37(9):1334-1344. PubMed ID: 28296047
[TBL] [Abstract][Full Text] [Related]
7. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications.
Bultas AC; Teshome B; Richter SK; Schafers S; Cooke E; Call WB
Ann Pharmacother; 2020 Jun; 54(6):583-593. PubMed ID: 31810371
[No Abstract] [Full Text] [Related]
8. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up.
Calès P; Bertrais S; Boursier J; Fouchard I; Oberti F;
Liver Int; 2021 Jan; 41(1):168-179. PubMed ID: 32979020
[TBL] [Abstract][Full Text] [Related]
9. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.
Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Kruzik M; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
Gastroenterology; 2014 Jun; 146(7):1680-90.e1. PubMed ID: 24631577
[TBL] [Abstract][Full Text] [Related]
10. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.
Scheiner B; Parada-Rodriguez D; Bucsics T; Schwabl P; Mandorfer M; Pfisterer N; Riedl F; Sieghart W; Ferlitsch A; Trauner M; Peck-Radosavljevic M; Reiberger T
Scand J Gastroenterol; 2017 Sep; 52(9):1008-1015. PubMed ID: 28532189
[TBL] [Abstract][Full Text] [Related]
11. Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.
Snoga JL; Lusk KA; Attridge RT; Attridge RL
Ann Pharmacother; 2020 Apr; 54(4):322-330. PubMed ID: 31701773
[No Abstract] [Full Text] [Related]
12. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
Bossen L; Krag A; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Jun; 63(6):1968-76. PubMed ID: 26599983
[TBL] [Abstract][Full Text] [Related]
13. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
Ascha MS; Hanouneh IA; Lopez R; Tamimi TA; Feldstein AF; Zein NN
Hepatology; 2010 Jun; 51(6):1972-8. PubMed ID: 20209604
[TBL] [Abstract][Full Text] [Related]
14. Nonselective β-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis.
Chirapongsathorn S; Valentin N; Alahdab F; Krittanawong C; Erwin PJ; Murad MH; Kamath PS
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1096-1104.e9. PubMed ID: 26829026
[TBL] [Abstract][Full Text] [Related]
15. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
16. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
17. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials.
Thiele M; Albillos A; Abazi R; Wiest R; Gluud LL; Krag A
Liver Int; 2015 Aug; 35(8):2009-16. PubMed ID: 25581713
[TBL] [Abstract][Full Text] [Related]
18. Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection.
Sasso R; Rockey DC
Aliment Pharmacol Ther; 2021 Feb; 53(3):418-425. PubMed ID: 33314175
[TBL] [Abstract][Full Text] [Related]
19. Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis.
Shin S; Lee SH; Lee M; Kim JH; Lee W; Lee HW; Park MS; Park S; Kim TS; Choi DH
Medicine (Baltimore); 2020 Feb; 99(9):e19008. PubMed ID: 32118712
[TBL] [Abstract][Full Text] [Related]
20. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.
Xu X; Guo X; De Stefano V; Silva-Junior G; Goyal H; Bai Z; Zhao Q; Qi X
Hepatol Int; 2019 Jul; 13(4):468-481. PubMed ID: 31175581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
